Daxor Unveils New FDA-Cleared BVA Analyzer Amid Strong Market Demand and Pivotal Clinical Data at HFSA
Daxor Corporation (DXR)
NASDAQ:AMEX Investor Relations:
daxor.com/investors
Company Research
Source: GlobeNewswire
Three Studies Validate BVA-Guided Care Significantly Cuts Hospital Readmissions and Boosts Survival in High-Cost Heart Failure Segments OAK RIDGE, TN, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces significant commercial momentum and clinical validation following the Heart Failure Society of America (HFSA) Annual Scientific Meeting. The company’s successful debut of its newly FDA-cleared, next-generation BVA analyzer signals a new era of data-driven fluid management for a multi-billion-dollar market. The initial response from clinicians confirmed robust market demand for the new system, driven by its enhanced ease of use, speed, and over 95% accuracy. New Clinical Data Validates Commercial Opportunity During the meeting, new clinical data presented from three leading institutions further validated Daxor’s BVA technology across critical, high-cost patient populations: Banner University
Show less
Read more
Impact Snapshot
Event Time:
DXR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DXR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DXR alerts
High impacting Daxor Corporation news events
Weekly update
A roundup of the hottest topics
DXR
News
- Daxor Fuels Growth with Three New Facility Adoptions and Deployment of Next-Generation BVA AnalyzerGlobeNewswire
- Daxor CEO Michael Feldschuh to Engage Investors at Exclusive Maxim Growth SummitGlobeNewswire
- Daxor’s New BVA Technology To Be Showcased At MedAxiom CV Transforum Fall '25GlobeNewswire
- Daxor Corporation Unveils Breakthrough Next-Gen BVA Analyzer at HFSA Annual Scientific Meeting [Yahoo! Finance]Yahoo! Finance
- Daxor Corporation Unveils Breakthrough Next-Gen BVA Analyzer at HFSA Annual Scientific MeetingGlobeNewswire
DXR
Sec Filings
- 11/14/25 - Form 4
- 10/20/25 - Form N-2/A
- 10/15/25 - Form N-CSR/A
- DXR's page on the SEC website